2025 / 02

Next Paper
DOI: 10.24075/brsmu.2025.022
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

OPINION

Therapeutic strategies for Wilson’s disease: current state and prospects

Ivanenko AV, Starodubova VD, Shokhina AG
About authors

Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Arina G. Shokhina
Ostrovityanova, 1, str. 1, Moscow, 117513, Russia; ur.xednay@anihkohs.g.a

About paper

Funding: the study was supported by the Russian Science Foundation grant (RSF grant No. 24-74-10106).

Author contribution: Ivanenko AV, Starodubova VD — manuscript writing; Shokhina AG — developing the concept, manuscript writing and editing, obtaining funding.

Received: 2025-04-02 Accepted: 2025-04-20 Published online: 2025-04-28
|
  1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s disease. Journal of Hepatology. 2012; 56 (3): 671–85. DOI: 10.1016/j.jhep.2011.11.007.
  2. Weiss KH, et al. Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease. Gastroenterology. 2011; 140 (4): 1189–98.e1. DOI: 10.1053/j.gastro.2010.12.034.
  3. Munk DE, et al. Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study. Sci Rep. 2022; 12 (1): 14714. DOI: 10.1038/s41598-022-18872-8.
  4. Solovyev N, Ala A, Schilsky M, Mills C, Willis K, Harrington CF. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry. Analytica Chimica Acta. 2020; 1098: 27–36. DOI: 10.1016/j.aca.2019.11.033.
  5. Snijders RJALM, et al. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. Journal of Hepatology. 2024; 80 (4): 576–85. DOI: 10.1016/j.jhep.2023.11.032.
  6. Medici V, Sturniolo GC. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs. 2008; 11 (8): 592–606.
  7. Fujiyoshi J, et al. Therapeutic potential of hepatocyte-like-cells converted from stem cells from human exfoliated deciduous teeth in fulminant Wilson’s disease. Sci Rep. 2019; 9 (1): 1535. DOI: 10.1038/s41598-018-38275-y.
  8. Sauer V, et al. Repeated transplantation of hepatocytes prevents fulminant hepatitis in a rat model of Wilson’s disease. Liver Transplantation. 2012; 8 (2): 248–59. DOI: 10.1002/lt.22466.
  9. Leng Y, et al. Long-Term Correction of Copper Metabolism in Wilson’s Disease Mice with AAV8 Vector Delivering Truncated ATP7B. Human Gene Therapy. 2019; 30 (12): 1494–504. DOI: 10.1089/hum.2019.148.
  10. Murillo O, et al. Liver Expression of a MiniATP7B Gene Results in Long–Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice. Hepatology. 2019; 70 (1): 108–26. DOI: 10.1002/hep.30535.
  11. Pöhler M, et al. CRISPR/Cas9-mediated correction of mutated copper transporter ATP7B. PLoS ONE. 2020; 15 (9): e0239411. DOI: 10.1371/journal.pone.0239411.
  12. Fontana M, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025; 392 (1): 33–44. DOI: 10.1056/NEJMoa2409134.
  13. Gillmore JD, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021; 385 (6): 493–502. DOI: 10.1056/NEJMoa2107454.
  14. Baxter M, et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. Journal of Hepatology. 2015; 62 (3): 581–9. DOI: 10.1016/j.jhep.2014.10.016.
  15. Suominen S, et al. Improvements in Maturity and Stability of 3D iPSC-Derived Hepatocyte-like Cell Cultures. Cells. 2023; 12 (19): 2368. DOI: 10.3390/cells12192368.